RU2012112943A - Соединения для лечения расстройства или заболевания, связанного с активностью нейрокининового 2 рецептора - Google Patents
Соединения для лечения расстройства или заболевания, связанного с активностью нейрокининового 2 рецептора Download PDFInfo
- Publication number
- RU2012112943A RU2012112943A RU2012112943/04A RU2012112943A RU2012112943A RU 2012112943 A RU2012112943 A RU 2012112943A RU 2012112943/04 A RU2012112943/04 A RU 2012112943/04A RU 2012112943 A RU2012112943 A RU 2012112943A RU 2012112943 A RU2012112943 A RU 2012112943A
- Authority
- RU
- Russia
- Prior art keywords
- compound according
- compound
- double bond
- formula
- disorder
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract 51
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims 11
- 201000010099 disease Diseases 0.000 title claims 6
- 230000000694 effects Effects 0.000 title claims 4
- 108010040722 Neurokinin-2 Receptors Proteins 0.000 title 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract 10
- 229910052799 carbon Inorganic materials 0.000 claims abstract 10
- 229910052760 oxygen Inorganic materials 0.000 claims abstract 10
- 239000001301 oxygen Substances 0.000 claims abstract 10
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims abstract 8
- 150000001721 carbon Chemical group 0.000 claims abstract 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract 6
- 150000003839 salts Chemical class 0.000 claims abstract 6
- 239000011203 carbon fibre reinforced carbon Substances 0.000 claims abstract 5
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims abstract 2
- 229910052717 sulfur Inorganic materials 0.000 claims abstract 2
- 239000011593 sulfur Substances 0.000 claims abstract 2
- 102000005962 receptors Human genes 0.000 claims 4
- 108020003175 receptors Proteins 0.000 claims 4
- 208000019901 Anxiety disease Diseases 0.000 claims 2
- 208000019022 Mood disease Diseases 0.000 claims 2
- 230000003001 depressive effect Effects 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 208000011117 substance-related disease Diseases 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- 208000030814 Eating disease Diseases 0.000 claims 1
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 1
- 101000831616 Homo sapiens Protachykinin-1 Proteins 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 102100024304 Protachykinin-1 Human genes 0.000 claims 1
- 206010046543 Urinary incontinence Diseases 0.000 claims 1
- 230000001430 anti-depressive effect Effects 0.000 claims 1
- 239000000935 antidepressant agent Substances 0.000 claims 1
- 229940005513 antidepressants Drugs 0.000 claims 1
- 210000000133 brain stem Anatomy 0.000 claims 1
- 235000014632 disordered eating Nutrition 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 206010013663 drug dependence Diseases 0.000 claims 1
- 230000003054 hormonal effect Effects 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 1
- 210000000653 nervous system Anatomy 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 208000023504 respiratory system disease Diseases 0.000 claims 1
- 208000012201 sexual and gender identity disease Diseases 0.000 claims 1
- 208000015891 sexual disease Diseases 0.000 claims 1
- 201000009032 substance abuse Diseases 0.000 claims 1
- 231100000736 substance abuse Toxicity 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 229910052727 yttrium Inorganic materials 0.000 abstract 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/003—Esters of saturated alcohols having the esterified hydroxy group bound to an acyclic carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/02—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen
- C07C69/22—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety
- C07C69/30—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety esterified with trihydroxylic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Addiction (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Reproductive Health (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24001409P | 2009-09-04 | 2009-09-04 | |
| US61/240,014 | 2009-09-04 | ||
| PCT/US2010/048006 WO2011029099A1 (en) | 2009-09-04 | 2010-09-07 | Compounds for treating disorders or diseases associated with neurokinin 2 receptor activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2012112943A true RU2012112943A (ru) | 2013-10-10 |
Family
ID=43649685
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2012112943/04A RU2012112943A (ru) | 2009-09-04 | 2010-09-07 | Соединения для лечения расстройства или заболевания, связанного с активностью нейрокининового 2 рецептора |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20120190743A1 (enExample) |
| EP (1) | EP2473038A4 (enExample) |
| JP (1) | JP2013503908A (enExample) |
| KR (1) | KR20120081120A (enExample) |
| CN (1) | CN102740693A (enExample) |
| AU (1) | AU2010289276A1 (enExample) |
| BR (1) | BR112012004988A2 (enExample) |
| CA (1) | CA2773035A1 (enExample) |
| MX (1) | MX2012002551A (enExample) |
| NZ (1) | NZ599215A (enExample) |
| RU (1) | RU2012112943A (enExample) |
| SG (1) | SG178964A1 (enExample) |
| WO (1) | WO2011029099A1 (enExample) |
| ZA (1) | ZA201202492B (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2508180A1 (en) * | 2011-04-04 | 2012-10-10 | Nestec S.A. | Sn-1(3) Monoacylglycerides and lipid absorption |
| EP3027199B1 (en) | 2013-08-01 | 2019-06-26 | Dignify Therapeutics, LLC | Compositions and methods for inducing urinary voiding and defecation |
| GB201315846D0 (en) | 2013-09-05 | 2013-10-23 | Imp Innovations Ltd | Method for treating or preventing hot flushes |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1001A (en) * | 1838-11-09 | Open grate fobj burning coai | ||
| GB820954A (en) * | 1956-05-02 | 1959-09-30 | Beecham Res Lab | Improvements in or relating to esters of 2,3-dimercaptopropanol |
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| JPS505309A (enExample) * | 1973-05-28 | 1975-01-21 | ||
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| JPH02131418A (ja) * | 1988-11-10 | 1990-05-21 | Sansho Seiyaku Co Ltd | 外用剤 |
| IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| DE4204151A1 (de) * | 1992-02-12 | 1993-08-19 | Schneider Manfred Prof Dr | Regioisomerenreine monoglyceride sowie ein verfahren zu ihrer herstellung durch enzymatische veresterung von glycerin in organischen loesungsmitteln |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| JPH0931020A (ja) * | 1995-07-25 | 1997-02-04 | Soda Koryo Kk | グリセロールモノ−６−ヒドロキシアルカン酸エステル、及びこれを含有する香料組成物 |
| SE9604582D0 (sv) * | 1996-12-13 | 1996-12-13 | Astra Ab | Novel compounds |
| CN100528829C (zh) * | 1999-11-18 | 2009-08-19 | R·L·佩德森 | 信息素或其成分的复分解合成 |
| MY141736A (en) * | 2002-10-08 | 2010-06-15 | Elanco Animal Health Ireland | Substituted 1,4-di-piperidin-4-yi-piperazine derivatives and their use as neurokinin antagonists |
| JO2676B1 (en) * | 2004-04-06 | 2012-06-17 | جانسين فارماسوتيكا ان. في | Derivatives of second-aza-spiro- (5,4) -dikan and their use as antihistamines |
| CN1286529C (zh) * | 2004-06-11 | 2006-11-29 | 华中科技大学 | 具有皮肤靶向性的药物组合物及其制备方法和用途 |
| US7906147B2 (en) * | 2006-10-12 | 2011-03-15 | Nanoprobes, Inc. | Functional associative coatings for nanoparticles |
| JP2011509262A (ja) * | 2008-01-11 | 2011-03-24 | ユナイテッド パラゴン アソシエイツ インコーポレイテッド | 受精卵分離物およびその使用 |
-
2010
- 2010-09-07 KR KR1020127008768A patent/KR20120081120A/ko not_active Withdrawn
- 2010-09-07 NZ NZ599215A patent/NZ599215A/en not_active IP Right Cessation
- 2010-09-07 SG SG2012015046A patent/SG178964A1/en unknown
- 2010-09-07 CN CN2010800501768A patent/CN102740693A/zh active Pending
- 2010-09-07 JP JP2012528118A patent/JP2013503908A/ja active Pending
- 2010-09-07 US US13/394,067 patent/US20120190743A1/en not_active Abandoned
- 2010-09-07 WO PCT/US2010/048006 patent/WO2011029099A1/en not_active Ceased
- 2010-09-07 MX MX2012002551A patent/MX2012002551A/es not_active Application Discontinuation
- 2010-09-07 EP EP10814632.5A patent/EP2473038A4/en not_active Withdrawn
- 2010-09-07 RU RU2012112943/04A patent/RU2012112943A/ru not_active Application Discontinuation
- 2010-09-07 BR BR112012004988A patent/BR112012004988A2/pt not_active Application Discontinuation
- 2010-09-07 AU AU2010289276A patent/AU2010289276A1/en not_active Abandoned
- 2010-09-07 CA CA2773035A patent/CA2773035A1/en not_active Abandoned
-
2012
- 2012-04-04 ZA ZA2012/02492A patent/ZA201202492B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112012004988A2 (pt) | 2015-09-08 |
| EP2473038A4 (en) | 2013-10-23 |
| MX2012002551A (es) | 2012-09-07 |
| NZ599215A (en) | 2014-11-28 |
| SG178964A1 (en) | 2012-04-27 |
| JP2013503908A (ja) | 2013-02-04 |
| CA2773035A1 (en) | 2011-03-10 |
| AU2010289276A1 (en) | 2012-05-03 |
| CN102740693A (zh) | 2012-10-17 |
| WO2011029099A1 (en) | 2011-03-10 |
| EP2473038A1 (en) | 2012-07-11 |
| KR20120081120A (ko) | 2012-07-18 |
| US20120190743A1 (en) | 2012-07-26 |
| ZA201202492B (en) | 2013-02-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA200801165A1 (ru) | Антагонисты неосновного рецептора-1 меланинконцентрирующего гормона | |
| JP2012530779A5 (enExample) | ||
| RU2012101947A (ru) | Способы лечения и профилактики усталости | |
| EA201000157A1 (ru) | Неосновные антагонисты рецептора меланин-концентрирующего гормона 1 типа и их применение | |
| EA201270144A1 (ru) | Комбинированная терапия при лечении диабета | |
| EA200700893A1 (ru) | Предшественники половых стероидов, одни или в сочетании с селективным модулятором эстрогеновых рецепторов, и/или с эстрогенами, и/или ингибитором цгмф-фосфодиэстераз 5 типа для профилактики и лечения вагинальной сухости и половой дисфункции у женщин в постменопаузе | |
| RU2009136592A (ru) | Терапевтические агенты | |
| RU2010143864A (ru) | Способы лечения нарушений с применением селективного антагониста nr2b-подтипа nmda рецепторов | |
| RU2010119458A (ru) | 1,3,5-тризамещенное производное триазола | |
| RU2007147420A (ru) | Органические соединения для лечения воспалительных или аллергических состояний | |
| JP2019529460A5 (enExample) | ||
| RU2013127420A (ru) | Способы уменьшения психогенного или компульсивного переедания | |
| RU2014111662A (ru) | Лечение кахексии | |
| RU2012136826A (ru) | Терапевтическое или профилактическое средство для заболеваний желчных путей | |
| JP2017503753A5 (enExample) | ||
| RU2012112943A (ru) | Соединения для лечения расстройства или заболевания, связанного с активностью нейрокининового 2 рецептора | |
| RU2010154417A (ru) | Комбинация частичного агониста никотиновых рецепторов и ингибитора ацетилхолинетеразы, содержащая ее фармацетическая композиция, и ее применение в лечении когнитивных расстройств | |
| JP5017268B2 (ja) | 覚醒を改善する方法 | |
| RU2017137008A (ru) | Антагонисты толл-подобного рецептора 4 и применение при аутоиммунных заболеваниях печени | |
| RU2008112181A (ru) | Применение конденсированных производных имидазола для лечения заболеваний, опосредованных рецептором ccr3 | |
| JP2006511604A5 (enExample) | ||
| RU2011138963A (ru) | Метаболиты, являющиеся церамидными аналогами | |
| JP2013503908A5 (enExample) | ||
| RU2014113967A (ru) | Комбинированная терапия рассеянного склероза интерфероном и андрографолидами | |
| MX2010006310A (es) | O-desmetil-venlafaxina para el tratamiento de transtorno depresivo mayor. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20150731 |
|
| FZ9A | Application not withdrawn (correction of the notice of withdrawal) |
Effective date: 20160727 |
|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20170302 |